BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24291296)

  • 1. Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain.
    Samala RV; Bloise R; Davis MP
    J Pain Symptom Manage; 2014 Jul; 48(1):132-6. PubMed ID: 24291296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain.
    Kornick CA; Santiago-Palma J; Schulman G; O'Brien PC; Weigand S; Payne R; Manfredi PL
    Cancer; 2003 Jun; 97(12):3121-4. PubMed ID: 12784350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
    Clemens KE; Klaschik E
    Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
    Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
    Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers.
    Mystakidou K; Parpa E; Tsilika E; Katsouda E; Kouloulias V; Kouvaris J; Georgaki S; Vlahos L
    J Pain; 2004 Mar; 5(2):119-32. PubMed ID: 15042520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl.
    Kornick CA; Santiago-Palma J; Khojainova N; Primavera LH; Payne R; Manfredi PL
    Cancer; 2001 Dec; 92(12):3056-61. PubMed ID: 11753984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)].
    Leppert W; Luczak J; Gorzelińska L; Kozikowska J
    Przegl Lek; 2000; 57(1):59-64. PubMed ID: 10907375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
    Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal fentanyl in cancer patients with moderate-to-severe pain: a prospective examination.
    Iconomou G; Viha A; Vagenakis AG; Kalofonos HP
    Anticancer Res; 2000; 20(6C):4821-4. PubMed ID: 11205226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid switching between transdermal fentanyl and methadone in cancer patients.
    Mercadante S; Ferrera P; Villari P; Casuccio A
    J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
    Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
    Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
    Tawfik MO; Bryuzgin V; Kourteva G;
    Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain.
    Nomura M; Inoue K; Matsushita S; Takahari D; Kondoh C; Shitara K; Ura T; Hayashi K; Kojima H; Kamata M; Tatematsu M; Hosoda R; Sawada S; Oka H; Muro K
    Clin J Pain; 2013 Jun; 29(6):487-91. PubMed ID: 23328324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
    J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trial.
    Kömürcü S; Turhal S; Altundağ K; Atahan L; Turna HS; Manavoğlu O; Yavuz AA; Ozkök S; Aliustaoğlu M; Altinbaş M; Pak Y; Cooper R; Yaylaci M; Demirkan B; Sarihan S; Ozdemir F
    Eur J Cancer Care (Engl); 2007 Jan; 16(1):67-73. PubMed ID: 17227355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
    Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
    Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
    Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.